NSRX insider transaction filings

Name: NSRX insider transaction filings (SEC Form 4)
Creator: FilingPulse
License: https://www.sec.gov/edgar

Nasus Pharma Ltd — 5 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-21. Screen NSRX transaction legs live →

Insider transaction summary — last 90 days

2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

Open-market purchases (code P, non-derivative): none reported.
Open-market sales (code S, non-derivative): none reported.
Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

Insider	Filings	Purchases (P)	Sales (S)	Other legs
Rubin Eyal — Chief Financial Officer	1	—	—	—
Teleman Dan Benjamin — Chief Executive Officer, Director	1	—	—	—

Recent Form 4 filings — Nasus Pharma Ltd

Filed	Form	Insider	Reported transactions	Source
2026-09-21	4	Rubin Eyal — Chief Financial Officer	Holdings only — no transactions reported	EDGAR
2026-07-29	4	Teleman Dan Benjamin — Chief Executive Officer, Director	Holdings only — no transactions reported	EDGAR
2026-06-22	4	Teleman Dan Benjamin — Chief Executive Officer, Director	Purchase (P): 6,550 @ $3.10	EDGAR
2026-04-22	4	Teleman Dan Benjamin — Chief Executive Officer, Director	Purchase (P): 2,900 @ $3.76	EDGAR
2026-04-01	4	Teleman Dan Benjamin — Chief Executive Officer, Director	Purchase (P): 15,000 @ $2.04	EDGAR

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=NSRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →